Grants and Contributions:
Title:
SARS-CoV-2 Point of Care Test Development
Agreement Number:
R&D-001
Agreement Value:
$1,624,553.00
Agreement Date:
Jun 18, 2020 - Dec 31, 2021
Description:
The objective of this Project is to develop and test a point of care (POC) diagnostic test for the SARS-CoV-2 virus. The tester will be usable in clinics, retirement homes, and will also be field portable with a battery power source.
Organization:
National Defence
Expected Results:
The key outcomes of the Project are the development of a tester that will have the capability of running a test for SARS-CoV2 on 1 to 12 patients simultaneously. The test as currently configures will use two tubes per patient. There are also controls to be run in the tester along with the patient samples. As a result the 12 tube tester will be able to run about 5 patent samples in a test run.
Location:
Toronto, Ontario, CA M9W 4Z4
Reference Number:
2021-2022-Q2-R&D-001
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Type:
For-profit organization
Amendment Date
Sep 28, 2021
Recipient's Operating Name:
Custom Biologics
Recipient's Legal Name:
MJMG Holdings Inc.
Federal Riding Name:
Etobicoke North (Ontario)
Program:
Innovation for Defence Excellence and Security Program - Innovation Networks
Program Purpose:
Collaborate with academic and private sector partners to build a network of expertise to support Canada’s current and future defence and security needs.
Amendments: